Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Neoplasm Metastasis 2Zollinger-Ellison Syndrome 1Vomiting 1Stomach Neoplasms 1Spinal Cord Compression 1Prostatic Neoplasms 1Pancreatitis 1Pancreatic Neoplasms 1Ototoxicity 1Osteosarcoma 1Helicobacter Infections 1Gastritis, Atrophic 1Gastrinoma 1Duodenal Neoplasms 1Delayed Bleeding 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumours 1

Interventions

Capecitabine 4Temozolomide 3Octreotide 3Leucovorin 3Fluorouracil 3Everolimus 3vatalanib 2Trastuzumab 2Streptozocin 2Oxaliplatin 2Doxorubicin 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1motesanib diphosphate 1epothilone B 1batifiban 1Thalidomide 1Sorafenib 1Pantoprazole 1Omeprazole 1Irinotecan 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Gefitinib 1Floxuridine 1Fentanyl 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × Pantoprazole × Clear all
NCT00001191 2017-07-02

The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid

National Institutes of Health Clinical Center (CC)

Phase 2 Completed

Zollinger-Ellison Syndrome, Gastrinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡